NeuraV
Non-pharmaceutical, minimally invasive solution for long-term reduction in the frequency and intensity of migraines
In production
Status
23.06.2025
Entry date
Problem to solve
a
Proposed solution
a
Request to H4
a
What this project changes in healthcare: the problem to solve
• Migraines affect 1 in 4 households, or approximately 12% of the global population
• They represent a major health problem, often underestimated despite their high prevalence
• Significant impact on patients’ quality of life and on the families concerned
• Limitation of professional, social and personal abilities related to attacks
The envisaged solution
• NeuraV: innovative, non-pharmacological solution for the treatment of migraines
• Based on existing, validated technology (CE and FDA approved) with a new indication
• Minimally invasive treatment offering an alternative to pharmacological approaches
• Aims to reduce the frequency and intensity of migraines safely and sustainably
Hands-on support from H4
• Support committee
• Connection with procurement experts
• Enable by design
What impact on the next steps of the project?
• In progress